DOCSLIB.ORG

B-Cell Reconstitution Recapitulates B-Cell Lymphopoiesis Following Haploidentical BM Transplantation and Post-Transplant CY

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
B-Cell Reconstitution Recapitulates B-Cell Lymphopoiesis Following Haploidentical BM Transplantation and Post-Transplant CY Bone Marrow Transplantation (2015) 50, 317–319 © 2015 Macmillan Publishers Limited All rights reserved 0268-3369/15 www.nature.com/bmt LETTER TO THE EDITOR B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY Bone Marrow Transplantation (2015) 50, 317–319; doi:10.1038/ From week 9, the proportion of transitional B cells progressively bmt.2014.266; published online 24 November 2014 decreased (not shown), whereas that of mature B cells increased (Figure 1d). To further evaluate the differentiation of mature cells, we included markers of naivety (IgM and IgD) and memory (IgG) in The treatment of many hematological diseases benefits from our polychromatic panel. At week 9, when a sufficient proportion myeloablative or non-myeloablative conditioning regimens of cells were available for the analysis, B cells were mostly naive followed by SCT or BMT. HLA-matched donors are preferred but and remained so for 26 weeks after haploBMT (Figure 1d). Despite not always available. Instead, haploidentical donors can be rapidly low, the proportion of memory B cells reached levels similar to identified. Unmanipulated haploidentical BMT (haploBMT) with that of marrow donors (Supplementary Figure 1D). non-myeloablative conditioning and post-transplant Cy has been To further investigate the steps of B-cell maturation, we developed to provide a universal source of BM donors.1 Cy, analyzed CD5, a regulator of B-cell activation, and CD21, a which depletes proliferating/allogeneic cells, prevents GVHD.1 component of the B-cell coreceptor complex, on transitional B Importantly, the infection-related mortality was remarkably low, cells. These surface markers characterize different stages of 5,6 5,6 suggesting effective immune reconstitution.1,2 However, a transitional B-cell development. Similarly to published data, detailed analysis in this regard is missing. Here we show the we observed three distinct transitional subsets during reconstitu- tion: T1 (CD5+CD21−), T2 (CD5+CD21+) and the CD5−CD21+ subset dynamics of the B-cell compartment. − − Ten consecutive patients were treated with the haploBMT (Figure 2a). In addition, we report an additional CD5 CD21 stage, protocol established by Luznik et al.1 (see Supplementary Methods here named T0, which precedes the aforementioned T1 and T2. for details; Supplementary Figure 1A). Patient characteristics are The differentiation status of transitional B cells shortly after BMT listed in Supplementary Table 1. Blood and BM were obtained was largely different between BM donors and patients and from Humanitas Cancer Center. Peripheral blood (PB) and BM significantly changed over time. At week 5, these cells mostly were processed and frozen in liquid nitrogen according to the displayed a T0 and, in smaller proportion, a T1 phenotype standard procedures and prepared for flow cytometry, as (Figure 2a). T0 cells progressively decreased in favor of T2 and − described.3 Non-parametric Wilcoxon rank test was used to CD5 CD21+ cells. No significant difference was detected between compare distributions. Differences in the pie chart distributions patients and BM donors at 14 weeks post haploBMT (Figure 2a). were calculated with SPICE software (National Institute of Allergy Transitional B-cell subsets in patients underwent a maturation and Infectious Diseases, Bethesda, MD, USA) by using a permuta- process leading to the generation of mature naive B cells, as they tion test. P-values are two sided and were considered significant progressively upregulated naive markers, that is, IgD, IgM and when ⩽ 0.05. CD217 (Figure 2b and Supplementary Figure 2). Notably, the Ten patients who underwent haploBMT were followed for a surface expression of IgM at week 15 was significantly higher median duration of 24 weeks (range: 5–26 weeks). B cells compared with that of transitional B cells from donors (CD3−CD14−CD19+CD20+) were not detected up to 4 weeks after (Supplementary Figure 2). haploBMT, suggesting that cells transferred with the graft did not In summary, a detailed longitudinal analysis of markers persist (Figure 1a). Rather, B cells appeared at week 4–5, tended to associated with B-cell differentiation shows that B cells are increase over time from week 7 and, in some patients, reached generated de novo following haploBMT. The B-cell compartment levels similar to that of the donors (Figure 1a). Analysis of donor– is initially characterized by the presence of transitional B cells and recipient chimerism of PB leukocytes (day 120) and of purified is progressively repopulated by mature naive B cells. The CD3−CD56−CD14−CD19+ B cells revealed that 498% of recipient differentiation of transitional B cells is characterized by a process cells carried donor alleles (Figure 1b). FACS analysis of the HLA of progressive maturation identified by CD5 and CD21 expression, haplotypes in donor–recipient pairs mismatched for HLA-A*02 as previously suggested.5,6 In humans, CD5 is expressed by confirmed the donor origin of the reconstituting B cells immature/transitional B cells and is downregulated by mature − (Supplementary Figure 1B). Recovering B cells were almost naive B cells,8 whereas CD21 distinguishes CD21 T1 from CD21+ Ki-67− at week 8 post BMT (Supplementary Figure 1C), suggesting T2 transitional stage.5,6 T1 are considered as precursors of T2 B that increase in the B-cell numbers was not due to the cells.7 Recently, pre-naive B cells, which are phenotypically naive homeostatic proliferation of transferred B cells.4 The phenotype but retain CD5 expression, have been described.5 Others referred of reconstituting B cells since 5 weeks post BMT was to cells with a similar phenotype and functional capacity, but − largely different from that of BM B cells; indeed, the former negative for CD5, as T3 transitional B cells.9 CD21 T1 cells were population predominantly displayed a CD38brightCD10+ immature/ proposed as the first to develop in the circulation following BMT.6 ‘transitional’ phenotype (that is, precursor of CD38dimCD10− Here, we integrate these data by using a polychormatic flow mature B cells), whereas the latter was mature (Figure 1c). At cytometry approach, and report a new putative transitional B-cell − − later time points, transitional cells were replaced by mature B cells stage, named T0, defined as CD5 CD21 . These cells are the first to (Figure 1c). Together, these data further indicate that B-cell appear during B-cell recovery. The B-cell maturation process from recovery depends on a new maturation process originating from T0 to naive B cells takes ~ 6 months to complete in haploBMT donor B-cell precursors. patients. Letter to the Editor 318 The small sample size could not allow to identify associations well as the functional capacity of the recovering B cells in this type between the extent of B-cell reconstitution and post-transplant of transplant. Patients receiving allogeneic transplants are complications. Future studies will need to address this aspect, as routinely vaccinated for multiple pathogens starting at 6 months ######### Host ***** Donor 800 3 9 PBMCs B cells 600 4 11 5 13 6 15 L 400 8 17 µ 300 Recipient PB 200 Donor BM Week 5 Week 8 Week 14 B cells/ Transitional 7.6% 100 98.2% 93.4% 44.4% 0 D89132226475116 10 1214 15 CD10 Weeks after BMT Mature: 92.4% 1.8% 6.6% 55.6% CD38 Mature Naive ********* ** ** 100 80 60 40 % of B cells 20 0 D89132226475116 10 1214 15 D 9 10 11 12 13 14 15 22 26 Weeks after BMT Figure 1. B-cell dynamics following haploBMT. (a) Absolute numbers (cells/μL) of circulating CD20+ B lymphocytes in transplanted patients at different time points after haploBMT compared with those of related BM donors (D). Single donor/recipient pairs are identified by different symbols, as depicted in the legend. Gray box indicates the range of peripheral B cells observed in healthy donors. (b) Proportions of donor- derived cells (gray) and residual host cells (black) in the PBMCs of the entire cohort of BM recipients (left pie, day 120) and in FACS-sorted B cells (right pie) from three BM recipients. (c) CD38 and CD10 expression in B cells in the donor BM and in the recipient. (d) Percent mature and naive B cells at different times post haploBMT. Data are shown as in a *,#Po0.05 vs D and week 4, respectively. Recipient PB CD21 IgD IgM Week 5 Week 8 Week 14 Donor PB 258 93 2864 T1 T2 39% 24% 12% 28% 13% 32% 35% 10% week 5 CD5 8.2% - + 432 506 4827 T0 5 21 7.6% 38% 40% CD21 week 8 Pie arcs: CD5+ CD21+ - + T2 5 21 569 640 7890 T1 T0 week 15 ** Patient D CD3+ * * *** Figure 2. B-cell recovery recapitulates B-cell ontogeny. (a) Representative example of CD5 and CD21 expression on CD38brightCD10+ transitional B cells (top) and proportions (pie chart at the bottom) of T0 (CD5−CD21−), T1 (CD5+CD21−), T2 (CD5+CD21+) and CD5−CD21+ B cells at different times post haploBMT. Arcs indicate the relative proportion of CD5+ (gray arc) and CD21+ cells (black arc). *Po0.05; **Po0.01; ***Po0.001. (b) CD21, IgD and IgM expression on transitional B cells identified as in a. Numbers in the plots indicate the median fluorescence intensity. CD3+ T cells are used as negative control. Bone Marrow Transplantation (2015) 317 – 319 © 2015 Macmillan Publishers Limited Letter to the Editor 319 after stem cell infusion. Our phenotypic data indicate that 3Department of Medical Biotechnologies and Translational Medicine triggering the B-cell pool with vaccination at this time would (BioMeTra), University of Milan, Milan, Italy and potentially induce Ab responses that are similar to those observed 4ImmunoTechnology Section, Vaccine Research Center, National in other transplantation settings. Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA E-mail: [email protected] or CONFLICT OF INTEREST [email protected] The authors declare no conflict of interest.
Load more

Recommended publications
  • B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells
    cells Review B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells Carlo G. Bonasia 1 , Wayel H. Abdulahad 1,2 , Abraham Rutgers 1, Peter Heeringa 2 and Nicolaas A. Bos 1,* 1 Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, 9713 Groningen, GZ, The Netherlands; [email protected] (C.G.B.); [email protected] (W.H.A.); [email protected] (A.R.) 2 Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, 9713 Groningen, GZ, The Netherlands; [email protected] * Correspondence: [email protected] Abstract: Autoreactive B cells are key drivers of pathogenic processes in autoimmune diseases by the production of autoantibodies, secretion of cytokines, and presentation of autoantigens to T cells. However, the mechanisms that underlie the development of autoreactive B cells are not well understood. Here, we review recent studies leveraging novel techniques to identify and characterize (auto)antigen-specific B cells. The insights gained from such studies pertaining to the mechanisms involved in the escape of tolerance checkpoints and the activation of autoreactive B cells are discussed. Citation: Bonasia, C.G.; Abdulahad, W.H.; Rutgers, A.; Heeringa, P.; Bos, In addition, we briefly highlight potential therapeutic strategies to target and eliminate autoreactive N.A. B Cell Activation and Escape of B cells in autoimmune diseases. Tolerance Checkpoints: Recent Insights from Studying Autoreactive Keywords: autoimmune diseases; B cells; autoreactive B cells; tolerance B Cells. Cells 2021, 10, 1190. https:// doi.org/10.3390/cells10051190 Academic Editor: Juan Pablo de 1.
    [Show full text]
  • Overview of B-Cell Maturation, Activation, Differentiation
    Overview of B-Cell Maturation, Activation, Differentiation B-Cell Development Begins in the Bone Marrow and Is Completed in the Periphery Antigen-Independent (Maturation) 1) Pro-B stages B-cell markers 2) Pre B-stages H- an L- chain loci rearrangements surrogate light chain 3) Naïve B-cell functional BCR . B cells are generated in the bone marrow. Takes 1-2 weeks to develop from hematopoietic stem (HSC) cells to mature B cells. Sequence of expression of cell surface receptor and adhesion molecules which allows for differentiation of B cells, proliferation at various stages, and movement within the bone marrow microenvironment. HSC passes through progressively more delimited progenitor-cell stages until it reaches the pro-B cell stage. Pre-B cell is irreversibly committed to the B-cell lineage and the recombination of the immunoglobulin genes expressed on the cell surface Immature B cell (transitional B cell) leaves the bone marrow to complete its maturation in the spleen through further differentiation. Immune system must create a repertoire of receptors capable of recognizing a large array of antigens while at the Source: Internet same time eliminating self-reactive B cells. B-Cell Activation and Differentiation • Exposure to antigen or various polyclonal mitogens activates resting B cells and stimulates their proliferation. • Activated B cells lose expression of sIgD and CD21 and acquire expression of activation antigens. Growth factor receptors, structures involved in cell-cell interaction, molecules that play a role in the localization and binding of activated B cells Two major types: T cell dependent (TD) T cell independent (TI) B-Cell Activation by Thymus-Independent and Dependent Antigens Source: Kuby T cell dependent: Involves protein antigens and CD4+ helper T cells.
    [Show full text]
  • B Cell Subsets in Autoimmune Disease B Cell Subsetsb Cell in Autoimmune Disease
    Thesis for doctoral degree (Ph.D.) 2018 Thesis for doctoral degree (Ph.D.) 2018 (Ph.D.) degree doctoral Thesis for B cell subsets in autoimmune disease B cell subsets in autoimmune disease B cell in autoimmune subsets Katrin Habir Katrin Habir From DEPARTMENT OF MEDICINE Karolinska Institutet, Stockholm, Sweden B CELL SUBSETS IN AUTOIMMUNE DISEASE Katrin Habir Stockholm 2018 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Printed by Eprint AB 2018 © Katrin Habir, 2018 ISBN 978-91-7676-900-3 B CELL SUBSETS IN AUTOIMMUNE DISEASE THESIS FOR DOCTORAL DEGREE (Ph.D.) AKADEMISK AVHANDLING som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i CMM Lecture Hall, L8:00, Center for Molecular Medicine (CMM), Karolinska Universitetssjukhuset, Solna. Friday February 2nd 2018 at 09.00 by Katrin Habir Principal Supervisor: Opponent: Dr. Stephen Malin Associate Professor Bengt Johansson Lindbom Karolinska Institutet Lunds Universitet Department of Medicine Department of Experimental Medical Science Division of Cardiovascular Medicine Division of Adaptive Immunity Co-supervisors: Examination Board: Professor Gunilla Karlsson Hedestam Professor Birgitta Heyman Karolinska Institutet Uppsala Universitet Department of Microbiology, Tumor and Cell Department of Medical Biochemistry and Biology Microbiology Division of Microbiology-Immunology Professor Dan Grandér Karolinska Institutet Associate Professor Lisa Westerberg Department of Oncology-Pathology Karolinska Institutet Department of Microbiology, Tumor and Cell Biology Associate Professor Angela Silveira Karolinska Institutet Department of Medicine Division of Cardiovascular Medicine “We still do not know one thousandth of one percent of what nature has revealed to us.” Albert Einstein THIS THESIS IS DEDICATED TO MY BELOVED ONES ABSTRACT B lymphocytes are a type of white blood cells, belonging to the adaptive arm of the immune system and involved in creating immunological memory.
    [Show full text]
  • Human B Cell Isolation Product Selection Diagram
    Human B Cell Isolation Product Selection Explore the infographic below to find the correct human B cell isolation product for your application. 1. Your Starting Sample Whole Peripheral Blood/Buffy Coat PBMCs/Leukapheresis Pack 2. Cell Separation Platform Immunodensity Cell Separation Immunomagnetic Cell Separation Immunomagnetic Cell Separation 3. Product Line RosetteSep™ EasySep™ EasySep™ Sequential Selection Negative Selection Negative Selection Positive Selection Negative Selection Positive Selection 4. Selection Method (Positive + Negative) iRosetteSep™ HLA iEasySep™ Direct HLA i, iiEasySep™ HLA iEasySep™ HLA B Cell viEasySep™ Human CD19 EasySep™ Human IgG+ B Cell Enrichment Cocktail B Cell Isolation Kit Chimerism Whole Blood Enrichment Kit Positive Selection Kit II Memory B Cell Isolation (15064HLA)1, 2, 3 (89684) / EasySep™ Direct B Cell Positive Selection (19054HLA)1, 2 (17854)1, 2 Kit (17868)1 (optional), 2' HLA Crossmatch B Cell Kit (17886)1, 2 Isolation Kit (19684 - 1, 2 RosetteSep™ Human available in the US only) iiiEasySep™ Human B Cell viEasySep™ Release EasySep™ Human Memory 5. Cell Isolation Kits B Cell Enrichment Cocktail i, iiEasySep™ HLA Enrichment Kit Human CD19 Positive B Cell Isolation Kit 1, 2, 3 1, 2 1, 2 1 (optional), 2 Catalog #s shown in ( ) (15024) Chimerism Whole Blood (19054) Selection Kit (17754) (17864) EasySep™ Direct Human CD19 Positive Selection B-CLL Cell Isolation Kit Kit (17874)1, 2 1, 2, 3, 4 *RosetteSep™ Human (19664) iiiEasySep™ Human B Cell EasySep™ Human CD138 Multiple Myeloma Cell Isolation Kit
    [Show full text]
  • Self-Reactive B Cells in the GALT Are Actively Curtailed to Prevent Gut Inflammation
    Self-reactive B cells in the GALT are actively curtailed to prevent gut inflammation Ashima Shukla, … , John R. Apgar, Robert C. Rickert JCI Insight. 2019;4(16):e130621. https://doi.org/10.1172/jci.insight.130621. Research Article Immunology Inflammation Immune homeostasis in the gut-associated lymphoid tissues (GALT) is critical to prevent the development of inadvertent pathologies. B cells, as the producers of antibodies and cytokines, play an important role in maintaining the GALT homeostasis. However, the mechanism by which B cells specifically direct their responses toward non-self-antigens and become ignorant to self-antigens in the GALT is not known. Therefore, we developed what we believe to be a novel mouse model by expressing duck egg lysozyme (DEL) in gut epithelial cells in presence of HEL-reactive B cells. Notably, we observed a transient activation and rapid deletion of self-reactive B cells in Peyer’s patches and mesenteric lymph nodes upon self-antigen exposure. The survival of self-reactive B cells upon exposure to their self-antigen was partially rescued by blocking receptor editing but could be completely rescued by stronger survival signal, such as ectopic expression of BCL2. Importantly, rescuing the self-reactive B cells promoted production of autoantibodies and gut inflammation. Mechanistically, we identify a specific activation of TGF-β signaling in self-reactive B cells in the gut and a critical role of this pathway in maintaining peripheral tolerance. Collectively, our studies describe functional consequences and the fate of self-reactive B cells in GALT and provide potentially novel mechanistic insights governing self-tolerance of B cells in the gut.
    [Show full text]
  • 1 the Immune System
    1 The immune system The immune response Innate immunity Adaptive immunity The immune system comprises two arms (rapid response) (slow response) functioning cooperatively to provide a Dendritic cell Mast cell comprehensive protective response: the B cell innate and the adaptive immune system. Macrophage γδ T cell T cell The innate immune system is primitive, does not require the presentation of an antigen, Natural and does not lead to immunological memory. killer cell Basophil Its effector cells are neutrophils, Complement protein macrophages, and mast cells, reacting Antibodies Natural Eosinophil killer T cell CD4+ CD8+ within minutes to hours with the help of T cell T cell complement activation and cytokines (CK). Granulocytes Neutrophil B-lymphocytes B-cell receptor The adaptive immune response is provided by the lymphocytes, which precisely recognise unique antigens (Ag) through cell-surface receptors. epitope Receptors are obtained in billions of variations through antigen cut and splicing of genes and subsequent negative T-lymphocytes selection: self-recognising lymphocytes are eradicated. T-cell receptor Immunological memory after an Ag encounter permits a faster and heightened state of response on a subsequent exposure. epitope MHC Lymphocytes develop in primary lymphoid tissue (bone marrow [BM], thymus) and circulate towards secondary Tonsils and adenoids Lymph lymphoid tissue (lymph nodes [LN], spleen, MALT). nodes Lymphatic vessels The Ag reach the LN carried by lymphocytes or by Thymus dendritic cells. Lymphocytes enter the LN from blood Lymph transiting through specialised endothelial cells. nodes The Ag is processed within the LN by lymphocytes, Spleen macrophages, and other immune cells in order to mount a specific immune response.
    [Show full text]
  • The Pathogenic Role of Innate Lymphoid Cells in Autoimmune-Related and Inflammatory Skin Diseases
    Cellular & Molecular Immunology www.nature.com/cmi REVIEW ARTICLE The pathogenic role of innate lymphoid cells in autoimmune-related and inflammatory skin diseases Suqing Zhou 1, Qianwen Li1, Haijing Wu1 and Qianjin Lu1 Innate lymphoid cells (ILCs), as an important component of the innate immune system, arise from a common lymphoid progenitor and are located in mucosal barriers and various tissues, including the intestine, skin, lung, and adipose tissue. ILCs are heterogeneous subsets of lymphocytes that have emerging roles in orchestrating immune response and contribute to maintain metabolic homeostasis and regulate tissue inflammation. Currently, more details about the pathways for the development and differentiation of ILCs have largely been elucidated, and cytokine secretion and downstream immune cell responses in disease pathogenesis have been reported. Recent research has identified that several distinct subsets of ILCs at skin barriers are involved in the complex regulatory network in local immunity, potentiating adaptive immunity and the inflammatory response. Of note, additional studies that assess the effects of ILCs are required to better define how ILCs regulate their development and functions and how they interact with other immune cells in autoimmune-related and inflammatory skin disorders. In this review, we will distill recent research progress in ILC biology, abnormal functions and potential pathogenic mechanisms in autoimmune-related skin diseases, including systemic lupus erythematosus (SLE), scleroderma and inflammatory diseases, as well as psoriasis and atopic dermatitis (AD), thereby giving a comprehensive review of the diversity and plasticity of ILCs and their unique functions in disease conditions with the aim to provide new insights into molecular diagnosis and suggest potential value in immunotherapy.
    [Show full text]
  • Transitional B Cells in Early Human B Cell Development – Time to Revisit the Paradigm?
    ORIGINAL RESEARCH published: 02 December 2016 doi: 10.3389/fimmu.2016.00546 Transitional B Cells in Early Human B Cell Development – Time to Revisit the Paradigm? Victoria G. Martin1†, Yu-Chang Bryan Wu2†, Catherine L. Townsend1, Grace H. C. Lu2, Joselli Silva O’Hare3, Alexander Mozeika4, Anthonius C. C. Coolen4, David Kipling5, Franca Fraternali2,4 and Deborah K. Dunn-Walters1,3* 1 Division of Infection, Immunity and Inflammatory Disease, Faculty of Life Sciences & Medicine, King’s College London, London, UK, 2 Randall Division of Cell and Molecular Biophysics, Faculty of Life Sciences & Medicine, King’s College London, Edited by: London, UK, 3 Faculty of Health and Medical Sciences, School of Biosciences and Medicine, University of Surrey, Guildford, Ana María Hernández, Surrey, UK, 4 Faculty of Life Sciences & Medicine, Institute for Mathematical and Molecular Biomedicine, King’s College Center of Molecular Immunology, London, London, UK, 5 Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK Cuba Reviewed by: The B cell repertoire is generated in the adult bone marrow by an ordered series of gene Tam Quach, Feinstein Institute for Medical rearrangement processes that result in massive diversity of immunoglobulin (Ig) genes Research, USA and consequently an equally large number of potential specificities for antigen. As the Harry W. Schroeder, process is essentially random, the cells exhibiting excess reactivity with self-antigens are University of Alabama at Birmingham, USA generated and need to be removed from the repertoire before the cells are fully mature. *Correspondence: Some of the cells are deleted, and some will undergo receptor editing to see if changing Deborah K.
    [Show full text]
  • Cd1d Regulates B Cell Development but Not B Cell Accumulation and IL10 Production in Mice with Pathologic CD5+ B Cell Expansion Victoria L
    Palmer et al. BMC Immunology (2015) 16:66 DOI 10.1186/s12865-015-0130-z RESEARCH ARTICLE Open Access Cd1d regulates B cell development but not B cell accumulation and IL10 production in mice with pathologic CD5+ B cell expansion Victoria L. Palmer, Vincent K. Nganga, Mary E. Rothermund, Greg A. Perry and Patrick C. Swanson* Abstract Background: CD1d is a widely expressed lipid antigen presenting molecule required for CD1d-restricted invariant natural killer T (iNKT) cell development. Elevated CD1d expression is detected in CD5+ IL10-producing B cells, called B10 B cells, and is correlated with poorer prognosis in chronic lymphocytic leukemia (CLL), a CD5+ B cell malignancy with B10-like functional properties. Whether CD1d expression regulates CD5+ B cell accumulation, IL10 competence, and antibody production in naïve mice with pathologic CD5+ B cell expansion remains untested. Results: Using three different transgenic mouse models of benign or leukemic CD5+ Bcellexpansion,wefoundthat CD1d was differentially expressed on CD5+ B cells between the three models, but loss of CD1d expression had no effect on CD5+ B cell abundance or inducible IL10 expression in any of the models. Interestingly, in the CLL-prone Eμ-TCL1 model, loss of CD1d expression suppressed spontaneous IgG (but not IgM) production, whereas in the dnRAG1xEμ-TCL1 (DTG) model of accelerated CLL, loss of CD1d expression was associated with elevated numbers of splenic CD4+ and CD8+ T cells and an inverted CD4+:CD8+ T cell ratio. Unexpectedly, before leukemia onset, all three transgenic CD1d-deficient mouse strains had fewer splenic transitional B cells than their CD1d-proficient counterparts.
    [Show full text]
  • High-Dimensional Flow-Cytometric Analysis of Human B-Cell Populations
    High-dimensional flow-cytometric analysis of human B-cell populations The BD FACSCelesta™ cell analyzer and FlowJo™ software together enable deep analysis of B-cell biology Features B-cell development is a stepwise process initiated in the fetal • High-resolution analysis of over 7 distinct liver and postnatal bone marrow and continued in the peripheral B-cell subsets using a 12-color panel lymphoid organs upon encounter with antigens. The various stages of B-cell differentiation can be identified by evaluating • Evaluation of distinct B-cell populations across different tissue types the expression and levels of distinct cell-surface markers, which are regulated throughout the course of B-cell differentiation. • Robust data analysis using the t-SNE analysis feature of FlowJo™ v10 software Multicolor flow cytometry is a powerful tool that has driven key discoveries in B-cell biology by facilitating the investigation of B-cell markers during cell development, differentiation and pathologies such as immunodeficiency, autoimmune disorders and malignancies. This datasheet describes a 12-color flow cytometry panel for the analysis of the most prominent B-cell subsets in human peripheral blood and bone marrow. The 12-color panel included markers uniquely expressed in certain cell subsets such as CD138 in plasma cells, as well as co-expressed markers (CD38 and CD24) (Figure 1A). The panel was designed to identify immature/transitional subsets (T1, T2 and T3), naive B cells, memory B-cell subsets, plasmablasts and plasma cells. The cells in the naive B-cell subset that uniquely express the ATP-binding cassette B1 (ABCB1) transporter were identified by analysis of cell extrusion of MitoTracker™ Green FM (ThermoFisher), a green-fluorescent mitochondrial stain.
    [Show full text]
  • Human Naive B Cells Cells by Cpg Oligodeoxynucleotide-Primed T+
    Presentation of Soluble Antigens to CD8+ T Cells by CpG Oligodeoxynucleotide-Primed Human Naive B Cells This information is current as Wei Jiang, Michael M. Lederman, Clifford V. Harding and of September 27, 2021. Scott F. Sieg J Immunol 2011; 186:2080-2086; Prepublished online 14 January 2011; doi: 10.4049/jimmunol.1001869 http://www.jimmunol.org/content/186/4/2080 Downloaded from References This article cites 36 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/186/4/2080.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Presentation of Soluble Antigens to CD8+ T Cells by CpG Oligodeoxynucleotide-Primed Human Naive B Cells Wei Jiang,*,† Michael M. Lederman,*,† Clifford V. Harding,†,‡ and Scott F. Sieg*,† Naive B lymphocytes are generally thought to be poor APCs, and there is limited knowledge of their role in activation of CD8+ T cells.
    [Show full text]
  • Plasma Cells: Finding New Light at the End of B Cell Development Kathryn L
    © 2001 Nature Publishing Group http://immunol.nature.com REVIEW Plasma cells: finding new light at the end of B cell development Kathryn L. Calame Plasma cells are cellular factories devoted entire- Upon plasma cell differentiation, there is a marked increase in ly to the manufacture and export of a single prod- steady-state amounts of Ig heavy and light chain mRNA and, when 2 uct: soluble immunoglobulin (Ig). As the final required for IgM and IgA secretion, J chain mRNA . Whether the increase in Ig mRNA is due to increased transcription, increased mediators of a humoral response, plasma cells mRNA stability or, as seems likely, both mechanisms, remains con- play a critical role in adaptive immunity.Although troversial2. There is also an increase in secreted versus membrane intense effort has been devoted to studying the forms of heavy chain mRNA, as determined by differential use of poly(A) sites that may involve the availability of one component of regulation and requirements for early B cell the polyadenylation machinery, cleavage-stimulation factor Cst-643. development, little information has been avail- To accommodate translation and secretion of the abundant Ig able on plasma cells. However, more recent mRNAs, plasma cells have an increased cytoplasmic to nuclear ratio work—including studies on genetically altered and prominent amounts of rough endoplasmic reticulum and secreto- ry vacuoles. mice and data from microarray analyses—has Numerous B cell–specific surface proteins are down-regulated begun to identify the regulatory cascades that upon plasma cell differentiation, including major histocompatibility initiate and maintain the plasma cell phenotype. complex (MHC) class II, B220, CD19, CD21 and CD22.
    [Show full text]